Compare GSK plc (GSK) vs Sherwin-Williams Company (The) Common Stock (SHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Sherwin-Williams Company (The) Common Stock — how do they compare? GSK plc trades at $48.29 (market cap $92.78B), while Sherwin-Williams Company (The) Common Stock trades at $327.77 (market cap $78.68B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.92%). Which is the better fit depends on your goals.
| GSK | SHW | |
|---|---|---|
Market Cap | $92.78B | $78.68B |
Volume | 5,756,402 | 1,245,324 |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $372.60 |
52-Week Low | $43.24 | $293.00 |
Typical Hold Time | 93 Days | — |
Enterprise Value | $112.77B | $92.60B |
Dividend Yield | 3.92% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.87, up 2.02% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by consistent revenue growth from $32.67B in 2025. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology expansion.
GSK presents a mixed outlook with solid fundamentals and strategic pipeline investments offset by technical weakness and patent cliff concerns. The stock offers value at 14.84 P/E but faces execution risks in oncology growth and HIV patent expirations. Analyst consensus leans cautious with 55% hold ratings.
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →
